全文获取类型
收费全文 | 2342607篇 |
免费 | 183886篇 |
国内免费 | 4507篇 |
专业分类
耳鼻咽喉 | 31859篇 |
儿科学 | 78859篇 |
妇产科学 | 66608篇 |
基础医学 | 336206篇 |
口腔科学 | 68724篇 |
临床医学 | 209768篇 |
内科学 | 452830篇 |
皮肤病学 | 51485篇 |
神经病学 | 189158篇 |
特种医学 | 92204篇 |
外国民族医学 | 753篇 |
外科学 | 353195篇 |
综合类 | 57813篇 |
现状与发展 | 3篇 |
一般理论 | 892篇 |
预防医学 | 183514篇 |
眼科学 | 54105篇 |
药学 | 173999篇 |
6篇 | |
中国医学 | 4460篇 |
肿瘤学 | 124559篇 |
出版年
2018年 | 22906篇 |
2016年 | 20121篇 |
2015年 | 23043篇 |
2014年 | 31696篇 |
2013年 | 48587篇 |
2012年 | 64968篇 |
2011年 | 68789篇 |
2010年 | 40945篇 |
2009年 | 38866篇 |
2008年 | 65403篇 |
2007年 | 69072篇 |
2006年 | 70174篇 |
2005年 | 67891篇 |
2004年 | 66657篇 |
2003年 | 63923篇 |
2002年 | 62286篇 |
2001年 | 107840篇 |
2000年 | 111390篇 |
1999年 | 94135篇 |
1998年 | 26233篇 |
1997年 | 23879篇 |
1996年 | 23647篇 |
1995年 | 23057篇 |
1994年 | 21623篇 |
1993年 | 20346篇 |
1992年 | 77222篇 |
1991年 | 75305篇 |
1990年 | 74022篇 |
1989年 | 71385篇 |
1988年 | 65870篇 |
1987年 | 65470篇 |
1986年 | 61809篇 |
1985年 | 59799篇 |
1984年 | 44951篇 |
1983年 | 38485篇 |
1982年 | 22816篇 |
1981年 | 20495篇 |
1980年 | 19191篇 |
1979年 | 42581篇 |
1978年 | 29998篇 |
1977年 | 25341篇 |
1976年 | 23854篇 |
1975年 | 25093篇 |
1974年 | 30680篇 |
1973年 | 29573篇 |
1972年 | 27133篇 |
1971年 | 25577篇 |
1970年 | 23554篇 |
1969年 | 22066篇 |
1968年 | 20265篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
993.
994.
Yubin Miao Said D Figueroa Darrell R Fisher Herbert A Moore Richard F Testa Timothy J Hoffman Thomas P Quinn 《Journal of nuclear medicine》2008,49(5):823-829
Peptide-targeted alpha-therapy with 7.4 MBq of (212)Pb-[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-ReO-[Cys(3,4,10),d-Phe(7),Arg(11)]alpha-MSH(3-13) ((212)Pb-DOTA-Re(Arg(11))CCMSH) cured 45% of B16/F1 murine melanoma-bearing C57 mice in a 120-d study, highlighting its melanoma treatment potential. However, there is a need to develop an imaging surrogate for patient-specific dosimetry and to monitor the tumor response to (212)Pb-DOTA-Re(Arg(11))CCMSH therapy. The purpose of this study was to evaluate the potential of (203)Pb-DOTA-Re(Arg(11))CCMSH as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH. METHODS: DOTA-Re(Arg(11))CCMSH was labeled with (203)Pb in 0.5 M NH(4)OAc buffer at pH 5.4. The internalization and efflux of (203)Pb-DOTA-Re(Arg(11))CCMSH were determined in B16/F1 melanoma cells. The pharmacokinetics of (203)Pb-DOTA-Re(Arg(11))CCMSH was examined in B16/F1 melanoma-bearing C57 mice. A micro-SPECT/CT study was performed with (203)Pb-DOTA-Re(Arg(11))CCMSH in a B16/F1 melanoma-bearing C57 mouse at 2 h after injection. RESULTS: (203)Pb-DOTA-Re(Arg(11))CCMSH was easily prepared in NH(4)OAc buffer and completely separated from the excess nonradiolabeled peptide by reversed-phase high-performance liquid chromatography (RP-HPLC). (203)Pb-DOTA-Re(Arg(11))CCMSH displayed fast internalization and extended retention in B16/F1 cells. Approximately 73% of (203)Pb-DOTA-Re(Arg(11))CCMSH activity internalized after a 20-min incubation at 25 degrees C. After incubation of the cells in culture medium for 20 min, 78% of internalized activity remained in the cells. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a biodistribution pattern similar to that of (212)Pb-DOTA-Re(Arg(11))CCMSH in B16/F1 melanoma-bearing mice. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor uptake of 12.00+/-3.20 percentage injected dose per gram (%ID/g) at 1 h after injection. The tumor uptake gradually decreased to 3.43+/-1.12 %ID/g at 48 h after injection. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor-to-kidney uptake ratio of 1.53 at 2 h after injection. The absorbed doses to the tumor and kidneys were 4.32 and 4.35 Gy, respectively, per 37 MBq. Whole-body clearance of (203)Pb-DOTA-Re(Arg(11))CCMSH was fast, with approximately 89% of the injected activity cleared through the urinary system by 2 h after injection. (203)Pb showed 1.6-mm SPECT resolution, which was comparable to (99m)Tc. Melanoma lesions were visualized through SPECT/CT images of (203)Pb-DOTA-Re(Arg(11))CCMSH at 2 h after injection. CONCLUSION: (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited favorable pharmacokinetic and tumor imaging properties, highlighting its potential as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH melanoma treatment. 相似文献
995.
996.
997.
998.
999.
1000.